SAB Biotherapeutics Stock Surges 32.3% Amid Advancements in COVID-19 and T1D Trials

Introduction

SAB Biotherapeutics Inc (NASDAQ: SABS) is a clinical-stage biopharmaceutical company headquartered in Miami, Florida, that develops fully human polyclonal antibody immunotherapies. Its proprietary DiversitAb™ platform utilizes genetically engineered transchromosomic bovine herds to produce disease-specific antibodies targeting type 1 diabetes (T1D), infectious diseases, and cancer.

Corporate Structure

Founded in 2014, SAB Biotherapeutics employs between 51 and 200 people. The executive team includes Samuel J. Reich as Chief Executive Officer—who previously served as CFO and Executive Chairman—Christoph Bausch as Executive Vice President & Chief Operating Officer, and Mark Conley as Vice President of Finance. The leadership team brings expertise in antibody science, clinical development, and corporate finance.

Polyclonal antibodies by Bilal O.

Developments and News

On October 4, 2021, SAB Biotherapeutics announced the dosing of the first patient in the Phase 3 ACTIV-2 trial of SAB-185, a fully human polyclonal antibody candidate for non-hospitalized patients with mild to moderate COVID-19. The candidate advanced from Phase 2 based on interim safety and efficacy criteria and is being evaluated against an active monoclonal antibody control.

On June 22, 2021, the company entered into a merger agreement with Big Cypress Acquisition Corp. Following the closing, expected in the fourth quarter of 2021, the combined entity will list on Nasdaq and hold approximately $118 million in pro forma cash, assuming no redemptions, at a post-merger enterprise value of $325 million.

On April 8, 2020, SAB Biotherapeutics and CSL Behring announced a partnership to develop SAB-185, combining CSL Behring’s manufacturing capabilities with SAB’s DiversitAb™ platform for COVID-19 therapeutics.

On July 17, 2025, SAB filed its definitive proxy statement (DEF 14A) for the Annual Meeting of Stockholders scheduled for that same day, with no proposed changes to board composition. On July 21, 2025, the company submitted a Form 8-K reporting governance updates and other current events.

Financial and Strategic Analysis

As of July 21, 2025, SAB Biotherapeutics’ share price was $3.40, an increase of 32.30% on a volume of 8,266,252 shares. The company has secured approximately $250 million in non-dilutive U.S. government funding and private financing, including a $175 million private placement in June 2025 to support the Phase 2b SAFEGUARD study of SAB-142, its lead therapy for T1D.

SAB is advancing clinical milestones across its pipeline. SAB-142 completed Phase 1 objectives and is progressing to a Phase 2b study. SAB-185 is enrolling in Phase 3 under the ACTIV-2 protocol. Additional proprietary programs in oncology and autoimmune disorders utilize the same transchromosomic bovine technology.

Market Position and Industry Context

SAB Biotherapeutics operates in the immunotherapy sector, differentiated by its production of fully human polyclonal antibodies instead of monoclonal formats. Polyclonal antibodies can target multiple epitopes and may maintain activity against emerging viral variants. The company competes with firms developing monoclonal and bispecific antibodies, cell therapies, and small-molecule immunomodulators. Collaborations with government agencies, CSL Behring, and academic institutions support both pandemic response efforts and the long-term development of treatments for chronic immune disorders.

tl;dr

On July 21, 2025, SAB Biotherapeutics’ stock rose 32.30% to $3.40 with 8.27 million shares traded. The company filed a Form 8-K detailing governance updates, continues Phase 3 dosing of SAB-185 for COVID-19, and expects to close its merger with Big Cypress Acquisition Corp. in Q4 2021. Funding from a $175 million private placement will support the Phase 2b study of SAB-142 in type 1 diabetes, with multiple clinical readouts anticipated throughout 2025.